UPSIT at baseline and 6-year change in clinical markers in pooled Het GBA and GD groups
| UPSIT>23 | UPSIT≤23 | P value (FP test)* | |
| UPSIT | −0.7±0.5 (33) | −5.0±3.1 (4) | 0.020† |
| UMSARS | 1.4±0.2 (40) | 2.8±1.0 (4) | 0.080 |
| RBDsq | 2.6±0.5 (32) | 1.7±0.3 (3) | 0.727 |
| MoCA | 1.5±0.4 (40) | −2±1.7 (3) | 0.022† |
| MDS-UPDRS III | 1.9±0.8 (40) | 10.0±5.3 (4) | 0.010† |
| BDI | 4.6±1.3 (29) | 17±6.1 (3) | 0.012† |
Difference between 6-year follow-up and baseline measurements. Data are reported as mean±SE (number of subjects).
*Non-parametric two-sample Fisher-Pitman permutation test. The statistic used is the difference in means of two samples. A false discovery rate of 5% was set using the Benjamini-Hochberg procedure.
†Significant result.
BDI, Beck Depression Inventory; GD, patients with Gaucher disease; MDS-UPDRS III, Movement Disorders Society Unified Parkinson’s Disease Rating Scale motor subscale; MoCA, Montreal Cognitive Assessment; RBDsq, REM Sleep Behavior Disorder screening questionnaire; UMSARS, Unified Multiple System Atrophy Rating Scale; UPSIT, University of Pennsylvania Smell Identification Test.